Molecular Partners AG Sponsored ADR
MOLN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.9%, EPS grew 34.3% and free cash flow grew 23.8%, each against the same quarter a year earlier.
Follow MOLN
Molecular Partners AG Sponsored ADR (MOLN) Piotroski F-score
Molecular Partners AG Sponsored ADR's Piotroski F-score for fiscal 2024 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2023.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2024 | 2 | 0.00 |
| FY2023 | 2 | (6.00) |
| FY2022 | 8 | 4.00 |
| FY2021 | 4 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (30.62%) | (27.85%) | Fail | 0 |
| Positive operating cash flow | (67.30m) | (65.73m) | Fail | 0 |
| Rising return on assets | (30.62%) | (27.85%) | Fail | 0 |
| Cash flow above net income | (5.91m) | 3.32m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 14.31 | 13.35 | Pass | 1 |
| No new shares issued | 34,033,000 | 32,771,000 | Fail | 0 |
| Rising gross margin | (877.95%) | (593.15%) | Fail | 0 |
| Rising asset turnover | 0.03 | 0.03 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CDXS Codexis, Inc. compare | 4 |
| MOLN Molecular Partners AG Sponsored ADR | 2 |
| NKTX Nkarta, Inc. compare | — |
| ALXO ALX Oncology Holdings Inc. compare | — |
| MSLE Satellos Bioscience Inc. compare | — |
| CNTN Canton Strategic Holdings, Inc. compare | — |
| TARA Protara Therapeutics, Inc. compare | — |
| NBP NovaBridge Biosciences compare | — |
| MENS Jyong Biotech Ltd. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover